{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:38:19Z","timestamp":1787647099109,"version":"build-2736575974"},"reference-count":124,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:00:00Z","timestamp":1650931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Dosing recommendations for anti-infective medicines in children with pre-existing kidney dysfunction are derived from adult pharmacokinetics studies and adjusted to kidney function. Due to neonatal\/pediatric age and kidney impairment, modifications in renal clearance and drug metabolism make standard anti-infective dosing for children and neonates inappropriate, with a risk of drug toxicity or significant underdosing. The aim of this study was the systematic description of the use of anti-infective medicines in pediatric patients with pre-existing kidney impairment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic review of the literature was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The EMBASE, Medline and Cochrane databases were searched on September 21st, 2021. Studies in all languages reporting data on pre-defined outcomes (pharmacokinetics-PK, kidney function, safety and efficacy) regarding the administration of anti-infective drugs in children up to 18 years with pre-existing kidney dysfunction were included.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>29 of 1,792 articles were eligible for inclusion. There were 13 case reports, six retrospective studies, nine prospective studies and one randomized controlled trial (RCT), reporting data on 2,168 pediatric patients. The most represented anti-infective class was glycopeptides, with seven studies on vancomycin, followed by carbapenems, with five studies, mostly on meropenem. Antivirals, aminoglycosides and antifungals counted three articles, followed by combined antibiotic therapy, cephalosporins, lipopeptides with two studies, respectively. Penicillins and polymixins counted one study each. Nine studies reported data on patients with a decreased kidney function, while 20 studies included data on kidney replacement therapy (KRT). Twenty-one studies reported data on PK. In 23 studies, clinical outcomes were reported. Clinical cure was achieved in 229\/242 patients. There were four cases of underdosing, one case of overdosing and 13 reported deaths.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This is the first systematic review providing evidence of the use of anti-infective medicines in pediatric patients with impaired kidney function or requiring KRT. Dosing size or interval adjustments in pediatric patients with kidney impairment vary according to age, critical illness status, decreased kidney function and dialysis type. Our findings underline the relevance of population PK in clinical practice and the need of developing predictive specific models for critical pediatric patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2022.868513","type":"journal-article","created":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T11:20:47Z","timestamp":1650972047000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Anti-infective Medicines Use in Children and Neonates With Pre-existing Kidney Dysfunction: A Systematic Review"],"prefix":"10.3389","volume":"10","author":[{"given":"Chiara","family":"Minotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Doni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Impieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Giaquinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Don\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.diabres.2020.108248","article-title":"Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference","volume":"97","author":"Levey","year":"2020","journal-title":"Kidney Int"},{"key":"B2","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/ckj\/sfw047","article-title":"Chronic kidney disease in children","volume":"9","author":"Becherucci","year":"2016","journal-title":"Clin Kidney J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1007\/s00467-005-1922-9","article-title":"Drug dosage in children with reduced renal function","volume":"20","author":"Daschner","year":"2005","journal-title":"Pediatr Nephrol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1002\/jcph.1676","article-title":"Dosing Recommendations for Pediatric Patients With Renal Impairment","volume":"60","author":"Al-Khouja","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1517\/14740338.2012.691964","article-title":"Detection and management of nephrotoxicity during drug development","volume":"11","author":"Loghman-Adham","year":"2012","journal-title":"Expert Opin Drug Saf"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1093\/jac\/dkv418","article-title":"The Worldwide Antibiotic Resistance and Prescribing in European Children (ARPEC) point prevalence survey: developing hospital-quality indicators of antibiotic prescribing for children","volume":"71","author":"Versporten","year":"2016","journal-title":"J Antimicrob Chemother."},{"key":"B7","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s15010-003-4130-1","article-title":"Prospective Survey of Antibiotic Utilization in Pediatric Hospitalized Patients to IdentifyTargets for Improvement of Prescription","volume":"31","author":"Potocki","year":"2003","journal-title":"Infection"},{"key":"B8","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.jhin.2007.04.018","article-title":"A point prevalence survey of hospital-acquired infections and antimicrobial use in a paediatric hospital in north-western Russia","volume":"66","author":"Hajdu","year":"2007","journal-title":"J Hosp Infect."},{"key":"B9","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.ijantimicag.2008.01.009","article-title":"A controlled intervention study to improve antibiotic use in a Russian paediatric hospital","volume":"31","author":"Berild","year":"2008","journal-title":"Int J Antimicrob Agents."},{"key":"B10","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jhin.2008.01.030","article-title":"A point prevalence study of infection and antimicrobial use at a UK children's hospital","volume":"68","author":"Ang","year":"2008","journal-title":"J Hosp Infect."},{"key":"B11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S1473-3099(10)70027-X","article-title":"Antibiotic prescribing in hospitals: a social and behavioural scientific approach","volume":"10","author":"Hulscher","year":"2010","journal-title":"Lancet Infect Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1093\/jac\/dks021","article-title":"Comparing neonatal and paediatric antibiotic prescribing between hospitals: a new algorithm to help international benchmarking","volume":"67","author":"Porta","year":"2012","journal-title":"J Antimicrob Chemother."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13756-019-0659-3","article-title":"Implementation and impact of pediatricantimicrobial stewardship programs:a systematic scoping review","volume":"9","author":"Don\u00e0","year":"2020","journal-title":"Antimicrob Resist Infect Control."},{"key":"B14","doi-asserted-by":"publisher","first-page":"S82","DOI":"10.1086\/499406","article-title":"The Relationship between Antimicrobial Resistance and Patient Outcomes: Mortality, Length of Hospital Stay, and Health Care Costs","volume":"42","author":"Cosgrove","year":"2006","journal-title":"Clin Infect Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1586\/14787210.6.5.751","article-title":"Clinical and economic burden of antimicrobial resistance","volume":"6","author":"Maragakis","year":"2008","journal-title":"Expert Rev Anti Infect Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2165\/00148581-200406010-00004","article-title":"Drug Dosing During Intermittent Hemodialysis and Continuous Renal Replacement Therapy Special Considerations in Pediatric Patients","volume":"6","author":"Veltri","year":"2004","journal-title":"Paediatr Drugs"},{"key":"B17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.2741\/s446","article-title":"Drug dosage in continuous venoveno hemofiltration in critically ill children","volume":"8","author":"Assadi","year":"2016","journal-title":"Front Biosci (Schol Ed)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ."},{"key":"B19","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ."},{"key":"B20","first-page":"1","volume-title":"Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies","year":"2014"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e138","DOI":"10.1097\/PCC.0000000000000656","article-title":"Continuous Infusion Vancomycin Through the Addition of Vancomycin to the Continuous Renal Replacement Therapy Solution in the PICU: a Case Series","volume":"17","author":"Cies","year":"2016","journal-title":"Pediatr Crit Care Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/jcpt.12842","article-title":"Intraperitoneal vancomycin in neonates during peritoneal dialysis: a case report","volume":"44","author":"Company-Albir","year":"2019","journal-title":"J Clin Pharm Ther"},{"key":"B23","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40272-019-00328-8","article-title":"Vancomycin prescribing and therapeutic drug monitoring in children with and without acute kidney injury after cardiac arrest","volume":"21","author":"Fitzgerald","year":"2019","journal-title":"Paediatr Drugs."},{"key":"B24","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40272-019-00343-9","article-title":"Vancomycin Use in a Paediatric Intensive Care Unit of a Tertiary Care Hospital","volume":"21","author":"Sridharan","year":"2019","journal-title":"Pediatric Drugs"},{"key":"B25","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s13318-019-00568-6","article-title":"Clinical Pharmacokinetics of Vancomycin in Critically Ill Children","volume":"44","author":"Sridharan","year":"2019","journal-title":"Eur J Drug Metabol Pharmacokinet."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1093\/ajhp\/zxaa244","article-title":"Intraperitoneal vancomycin treatment of multifocal methicillin-resistant Staphylococcus aureus osteomyelitis in a patient on peritoneal dialysis","volume":"77","author":"Abid","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"B27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1208\/s12248-021-00577-x","article-title":"Dosing Recommendations for Vancomycin in Children and Adolescents with Varying Levels of Obesity and Renal Dysfunction: a Population Pharmacokinetic Study in 1892 Children Aged 1\u201318 Years","volume":"23","author":"Smit","year":"2021","journal-title":"AAPS J"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s004670100015","article-title":"Meropenem pharmacokinetics in childrenand adolescents receiving hemodialysis","volume":"16","author":"Goldstein","year":"2001","journal-title":"Pediatr Nephrol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1097\/01.ccm.0000510524.47813.84","article-title":"Continuous infusion of meropenem in a patient on ECMO and CRRT","volume":"44","author":"Alqaqaa","year":"2016","journal-title":"Crit Care Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"92","DOI":"10.5863\/1551-6776-21.1.92","article-title":"Pharmacokinetics of Continuous Infusion Meropenem With Concurrent Extracorporeal Life Support and Continuous Renal Replacement Therapy: a Case Report","volume":"21","author":"Cies","year":"2016","journal-title":"J Pediatr Pharmacol Ther"},{"key":"B31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00228-019-02761-7","article-title":"Population pharmacokinetics of meropenem in critically ill children with different renal functions","volume":"76","author":"Rapp","year":"2020","journal-title":"Eur J Clin Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1097\/0.1mat.0000225268.28044.ae","article-title":"Pharmacokinetics and the Most Suitable Regimen of Panipenem\/Beta Mipron in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Pilot Study","volume":"52","author":"Hayakawa","year":"2006","journal-title":"ASAIO J"},{"key":"B33","doi-asserted-by":"publisher","first-page":"E153","DOI":"10.1111\/j.1399-3046.2011.01489.x","article-title":"Oseltamivir-resistant 2009 H1N1 influenza pneumonia during therapy in a renal transplant recipient","volume":"16","author":"Shetty","year":"2012","journal-title":"Pediatr Transplantat"},{"key":"B34","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/phar.1526","article-title":"Therapeutic Drug Monitoring of Continuous-Infusion Acylovir for Disseminated Herpes Simplex Virus Infection in a Neonate Receiving Concurrent Extracorporeal Life Support and Continuous Renal Replacement Therapy","volume":"35","author":"Cies","year":"2015","journal-title":"Pharmacotherapy."},{"key":"B35","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1007\/s00467-021-05111-x","article-title":"Favipiravir use in children with COVID-19 and acute kidney injury: is it safe?","volume":"36","author":"Ozsurekci","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1136\/adc.53.4.334","article-title":"Dosage schedule of gentamicin for chronic renal insufficiency in children","volume":"53","author":"Yoshioka","year":"1978","journal-title":"Arch Dis Child."},{"key":"B37","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0022-3476(80)80841-9","article-title":"Determining gentamicin dosage children with renal failure","volume":"96","author":"Sirinavin","year":"1980"},{"key":"B38","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/ki.1981.112","article-title":"Pharmacokinetics of amikacin in children with normal and impaired renal function","volume":"20","author":"Lanao","year":"1981","journal-title":"Kidney Int"},{"key":"B39","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1681\/ASN.V101136","article-title":"Intermittent versus Continuous Intraperitoneal Glycopeptide\/Ceftazidime Treatment in Children with Peritoneal Dialysis-Associated Peritonitis","volume":"10","author":"Schaefer","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1007\/s15010-005-5074-4","article-title":"Peritonitis Due to Neisseria mucosa in an Adolescent Receiving Peritoneal Dialysis","volume":"33","author":"Shetty","year":"2005","journal-title":"Infection"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e02006","DOI":"10.1128\/AAC.02006-18","article-title":"Cefepime pharmacokinetics in critically ill pediatric patients receiving continuous renal replacement therapy","volume":"63","author":"Stitt","year":"2019","journal-title":"Antimicrob Agents Chemother."},{"key":"B42","doi-asserted-by":"publisher","first-page":"887","DOI":"10.3390\/antibiotics9120887","article-title":"Finding the Dose for Ceftolozane-Tazobactam in Critically Ill Children with and without Acute Kidney Injury","volume":"9","author":"Butrague\u00f1o-Laiseca","year":"2020","journal-title":"Antibiotics."},{"key":"B43","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/IPC.0b013e3182294bc5","article-title":"Linezolid- and Vancomycin-Resistant Enterococcus Faecium Peritonitis and Bacteremia Successfully Treated With Daptomycin in an Immunocompromised Pediatric Patient With Hepatic and Renal Failure","volume":"20","author":"Chan","year":"2012","journal-title":"Infect Dis Clin Pract"},{"key":"B44","doi-asserted-by":"publisher","first-page":"300","DOI":"10.5863\/1551-6776-22.4.300","article-title":"The Use of Daptomycin to Treat Methicillin-Resistant Staphylococcus Epidermidis Bacteremia in a Critically Ill Child with Renal Failure","volume":"22","author":"Morris","year":"2017","journal-title":"J Pediatr Pharmacol Ther"},{"key":"B45","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1093\/jac\/dkg419","article-title":"Treatment of candidaemia in premature infants: comparison of three amphotericin B preparations","volume":"52","author":"Linder","year":"2003","journal-title":"J Antimicrob Chemother."},{"key":"B46","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.kjms.2011.06.007","article-title":"Complicated Candida parapsilosis peritonitis on peritoneal dialysis in a neonate with renal failure because of bilateral adrenal abscesses","volume":"27","author":"Cheng","year":"2011","journal-title":"Kaohsiung J Med Sci"},{"key":"B47","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1093\/jac\/dkaa356","article-title":"Temocillin dosage adjustment in a preterm infant with severe renal disease: a case report","volume":"75","author":"Dumangin","year":"2020","journal-title":"J Antimicrob Chemother."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1097\/BCR.0b013e318203352a","article-title":"Pharmacokinetics of Colistin in an Adolescent Boy With Extensive Burn Injury","volume":"32","author":"Healy","year":"2011","journal-title":"J Burn Care Res"},{"key":"B49","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1097\/FTD.0000000000000641","article-title":"Fluconazole Exposure in Plasma and Bile During Continuous Venovenous Hemodialysis","volume":"41","author":"Oualha","year":"2019","journal-title":"Ther Drug Monit"},{"key":"B50","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.ijantimicag.2011.12.011","article-title":"Augmented renal clearance in septic patients and implications for vancomycin optimisation","volume":"39","author":"Baptista","year":"2012","journal-title":"Int J Antimicrob Agents."},{"key":"B51","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1097\/CCM.0b013e3181961bff","article-title":"Pharmacokinetic issues for antibiotics in the critically ill patient","volume":"37","author":"Roberts","year":"2009","journal-title":"Crit Care Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1093\/cid\/cir531","article-title":"Pediatric Infectious Diseases Society and the Infectious Diseases Society of America: The management of community-acquired pneumonia in infants and children older than 3 months of age: Clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America","volume":"53","author":"Bradley","year":"2011","journal-title":"Clin Infect Dis."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Infectious Diseases Society of America: Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis."},{"key":"B54","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1086\/600877","article-title":"Vancomycin therapeutic guidelines: A summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists","volume":"49","author":"Rybak","year":"2009","journal-title":"Clin Infect Dis."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1086\/425368","article-title":"Practice guidelines for the management of bacterial meningitis","volume":"39","author":"Tunkel","year":"2004","journal-title":"Clin Infect Dis."},{"key":"B56","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillinresistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatr","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"B57","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/jac\/dkr442","article-title":"Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: Systematic review and meta-analysis","volume":"67","author":"Cataldo","year":"2012","journal-title":"J Antimicrob Chemother."},{"key":"B58","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/2110-5820-2-22","article-title":"Continuous infusion of antibiotics in the critically ill: The new holy grail for beta-lactams and vancomycin?","volume":"2","author":"Van Herendael","year":"2012","journal-title":"Ann Intensive Care."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1128\/AAC.45.9.2460-2467.2001","article-title":"Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: Prospective multicenter randomized study","volume":"45","author":"Wysocki","year":"2001","journal-title":"Antimicrob Agents Chemother."},{"key":"B60","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2165\/00003088-199426060-00004","article-title":"Clinical pharmacokinetics during continuous haemofiltration","volume":"26","author":"Bressolle","year":"1994","journal-title":"Clin Pharmacokinet."},{"key":"B61","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.1365-2125.2004.02143.x","article-title":"Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration","volume":"58","author":"DelDot","year":"2004","journal-title":"Br J Clin Pharmacol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ijantimicag.2012.10.018","article-title":"Continuous infusion of vancomycin in septic patients receiving continuous renal replacement therapy","volume":"41","author":"Covajes","year":"2013","journal-title":"Int J Antimicrob Agents."},{"key":"B63","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3747\/pdi.2011.00091","article-title":"Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update","volume":"32","author":"Warady","year":"2012","journal-title":"Perit Dial Int"},{"key":"B64","year":"","journal-title":"British National Formulary for Children (BNFc)."},{"key":"B65","first-page":"S11","article-title":"The pharmacokinetics of meropenem","volume":"96","author":"Drusano","year":"1995","journal-title":"Scand J Infect Dis."},{"key":"B66","doi-asserted-by":"publisher","first-page":"S249","DOI":"10.1093\/clinids\/24.Supplement_2.S249","article-title":"Pharmacokinetics of meropenem in animals, healthy volunteers and patients","volume":"24","author":"Moon","year":"1997","journal-title":"Clin Infect Dis."},{"key":"B67","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1128\/AAC.36.12.2794","article-title":"Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment","volume":"36","author":"Leroy","year":"1992","journal-title":"Antimicrob Agents Chemother."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1128\/AAC.36.7.1532","article-title":"Pharmacokinetics of meropenem in subjects with varying degrees of renal impairment","volume":"36","author":"Christensson","year":"1992","journal-title":"Antimicrob Agents Chemother."},{"key":"B69","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/BF00314864","article-title":"Pharmacokinetics of meropenem in subjects with renal insufficiency","volume":"42","author":"Leroy","year":"1992","journal-title":"Eur J Clin Pharmacol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1093\/jac\/36.suppl_A.63","article-title":"The pharmacokinetics of meropenem in infants and children: a population analysis","volume":"36","author":"Parker","year":"1995","journal-title":"J Antimicrob Chemother."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/S0149-2918(04)80001-8","article-title":"Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem","volume":"26","author":"Mattoes","year":"2004","journal-title":"Clin Ther."},{"key":"B72","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1086\/514622","article-title":"The pharmacodynamics of beta-lactams","volume":"27","author":"Turnidge","year":"1998","journal-title":"Clin Infect Dis."},{"key":"B73","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1128\/AAC.37.2.229","article-title":"Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease","volume":"37","author":"Chimata","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"B74","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2165\/00003495-200363090-00005","article-title":"Panipenem\/betamipron","volume":"63","author":"Goa","year":"2003","journal-title":"Drugs."},{"key":"B75","first-page":"241","article-title":"Overview of a new carbapenem, panipenem\/betamipron","volume":"20","author":"Shimada","year":"1994","journal-title":"Drugs Exp Clin Res."},{"key":"B76","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1016\/j.xphs.2020.06.010","article-title":"A Physiologically Based Pharmacokinetic Model of Ertapenem in Pediatric Patients With Renal Impairment","volume":"109","author":"Ye","year":"2020","journal-title":"J Pharm Sci"},{"key":"B77","first-page":"151","article-title":"Reflections on the clinical pharmacology of gentamicin","author":"Hewitt","year":"1973","journal-title":"Acta Pathol Microbiol Scand B Microbiol Immunol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1128\/AAC.8.1.58","article-title":"Gentamicin blood levels: a guide to nephrotoxicity","volume":"8","author":"Dahlgren","year":"1975","journal-title":"Antimicrob Ag Chemother."},{"key":"B79","first-page":"55","article-title":"Gentamicin: toxicity in prospective","volume":"50","author":"Hewitt","year":"1974","journal-title":"Postgrad Med J."},{"key":"B80","first-page":"58","article-title":"Prospective study of the ototoxicity of gentamicin","author":"Nordstrom","year":"1973","journal-title":"Acta Pathol Microbiol Scand B Microbiol Immunol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1001\/jama.1972.03190340043010","article-title":"Correlation of serum creatinine concentration and gentamicin half-life","volume":"219","author":"Cutler","year":"1972","journal-title":"JAMA."},{"key":"B82","volume-title":"2018 Nelson's Pediatric Antimicrobial Therapy","author":"Bradley","year":"2012"},{"key":"B83","first-page":"77","article-title":"Pharmacokinetics of aminoglycosides: General considerations","volume":"62","author":"Dittert","year":"1977","journal-title":"Am J Med"},{"key":"B84","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1128\/AAC.38.5.931","article-title":"Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model","volume":"38","author":"Mouton","year":"1994","journal-title":"Antimicrob Agents Chemother."},{"key":"B85","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.ijantimicag.2010.06.008","article-title":"Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept","volume":"36","author":"Roberts","year":"2010","journal-title":"Int J Antimicrob Agents."},{"key":"B86","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1093\/jac\/dkf130","article-title":"Pharmacodynamics of cefepime in patients with Gram-negative infections","volume":"50","author":"Tam","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"B87","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.ijantimicag.2007.12.009","article-title":"Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T_MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections","volume":"31","author":"McKinnon","year":"2008","journal-title":"Int J Antimicrob Agents."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: defining antibiotic levels in intensive care unit patients: are current Beta-lactam antibiotic doses sufficient for critically ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin Infect Dis."},{"key":"B89","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.ijantimicag.2014.12.018","article-title":"Cefepime free minimum concentration to minimum inhibitory concentration (fCmin\/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia","volume":"45","author":"Aitken","year":"2015","journal-title":"Int J Antimicrob Agents."},{"key":"B90","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1093\/jpids\/piz002","article-title":"Defining the Role of Novel Beta-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms","volume":"8","author":"Tamma","year":"2019","journal-title":"J Pediatric Infect Dis Soc."},{"key":"B91","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/cpdd.429","article-title":"Safety, Tolerability, and Pharmacokinetics of 3 g of Ceftolozane\/Tazobactam in Healthy Adults: A Randomized, Placebo-Controlled, Multiple-Dose Study","volume":"7","author":"Yu","year":"2018","journal-title":"Clin Pharmacol Drug Dev."},{"key":"B92","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1128\/AAC.02151-13","article-title":"Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam","volume":"58","author":"Wooley","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"B93","doi-asserted-by":"publisher","first-page":"ofy280","DOI":"10.1093\/ofid\/ofy280","article-title":"Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: a multicenter study","volume":"5","author":"Gallagher","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"B94","doi-asserted-by":"publisher","first-page":"e02578","DOI":"10.1128\/AAC.02578-18","article-title":"Ceftolozane-Tazobactam Population Pharmacokinetics and Dose Selection for Further Clinical Evaluation in Pediatric Patients with Complicated Urinary Tract or Complicated Intra-abdominal Infections. Antimicrob","volume":"63","author":"Larson","year":"2019","journal-title":"Agents Chemother"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/INF.0000000000002170","article-title":"Pharmacokinetics and Safety of Single Intravenous Doses of Ceftolozane\/Tazobactam in ChildrenWith Proven or Suspected Gram-Negative Infection","volume":"37","author":"Bradley","year":"2018","journal-title":"Pediatr Infect Dis J."},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-3402719","article-title":"Ceftolozane\/Tazobactam in Neonates and Young Infants: The Challenges of Collecting Pharmacokinetics and Safety Data in This Vulnerable Patient Population","author":"Ang","year":"2020","journal-title":"Am J Perinatol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000455897","article-title":"Ex vivo Ceftolozane\/Tazobactam Clearance during Continuous Renal Replacement Therapy","volume":"44","author":"Chaijamorn","year":"2017","journal-title":"Blood Purif."},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2021.10.003","article-title":"Pharmacokinetics of ceftolozane\/tazobactam continuous infusion on renal replacement therapy: a pediatric case report","author":"Collignon","year":"2021","journal-title":"Therapie"},{"key":"B99","doi-asserted-by":"publisher","first-page":"786301","DOI":"10.1155\/2014\/786301","article-title":"Citrate anticoagulation for CRRT in children: Comparison with heparin","volume":"2014","author":"Fern\u00e1ndez","year":"2014","journal-title":"Biomed Res Int."},{"key":"B100","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s40262-017-0584-7","article-title":"Pharmacokinetics and pharmacodynamics of temocillin","volume":"57","author":"Alexandre","year":"2018","journal-title":"Clin Pharmacokinet."},{"key":"B101","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1093\/jac\/dkn511","article-title":"Temocillin revived","volume":"63","author":"Livermore","year":"2009","journal-title":"J Antimicrob Chemother."},{"key":"B102","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/jac\/11.4.349","article-title":"The pharmacokinetics of temocillin in patients with normal and impaired renal function","volume":"11","author":"Boelaert","year":"1983","journal-title":"J Antimicrob Chemother."},{"key":"B103","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/jac\/12.1.47","article-title":"Pharmacokinetics of temocillin (BRL17421) in subjects with normal and impaired renal function","volume":"12","author":"Leroy","year":"1983","journal-title":"J Antimicrob Chemother."},{"key":"B104","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1128\/AAC.45.3.781-785.2001","article-title":"In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis","volume":"45","author":"Li","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1128\/AAC.01114-09","article-title":"Elucidation of the pharmacokinetic\/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models","volume":"54","author":"Dudhani","year":"2010","journal-title":"Antimicrob Agents Chemother."},{"key":"B106","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.clinthera.2008.01.015","article-title":"Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, Gramnegative bacilli infections: a prospective, open-label, uncontrolled study","volume":"30","author":"Markou","year":"2008","journal-title":"Clin Ther"},{"key":"B107","doi-asserted-by":"publisher","first-page":"4814","DOI":"10.1128\/AAC.49.11.4814-4815.2005","article-title":"Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration","volume":"49","author":"Li","year":"2005","journal-title":"Antimicrob Agents Chemother."},{"key":"B108","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1093\/jac\/dkh167","article-title":"Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate","volume":"53","author":"Li","year":"2004","journal-title":"J Antimicrob Chemother."},{"key":"B109","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1177\/089686089101100311","article-title":"Antimicrobial treatment of peritonitis associated with continuous ambulatory peritoneal dialysis","volume":"11","author":"Millikin","year":"1991","journal-title":"Perit Dial Int."},{"key":"B110","first-page":"141","volume":"10","year":"1994","journal-title":"Adv Perit Dial"},{"key":"B111","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/089686089301300106","article-title":"Peritoneal dialysis-related peritonitis treatment recommendations: 1993 update","volume":"13","author":"Keane","year":"1993","journal-title":"Perit Dial Int."},{"key":"B112","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/01.inf.0000435509.75114.3d","article-title":"Population pharmacokinetics of intravenous acyclovir in preterm and term infants","volume":"33","author":"Sampson","year":"2014","journal-title":"Pediatr Infect Dis J."},{"key":"B113","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1055\/s-0029-1241187","article-title":"Efficacy of continuous acyclovir infusion in neonatal herpes virus encephalitis","volume":"40","author":"Kakisaka","year":"2009","journal-title":"Neuropediatrics."},{"key":"B114","doi-asserted-by":"publisher","first-page":"e0005389","DOI":"10.1371\/journal.pntd.0005389","article-title":"Favipiravir pharmacokinetics in Ebola-infected patients of the JIKI trial reveals concentrations lower than targeted","volume":"11","author":"Nguyen","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"B115","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40268-020-00333-0","article-title":"Recommendations for dosing of repurposed COVID-19 medications in patients with renal and hepatic impairment","volume":"21","author":"Marra","year":"2021","journal-title":"Drugs R D."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.kint.2020.03.015","article-title":"COVID-19 therapeutic options for patients with kidney disease","volume":"7","author":"Izzedine","year":"2020","journal-title":"Kidney Int"},{"key":"B117","unstructured":"SiseME\n          Pharmacologic Treatment of COVID-19: What Nephrologists Need to Know.2020"},{"key":"B118","volume-title":"The Sanford Guide to Antimicrobial therapy 2021","author":"Gilbert","year":"2021"},{"key":"B119","doi-asserted-by":"publisher","first-page":"10","DOI":"10.2165\/00003088-199324010-00002","article-title":"Clinical pharmacokinetics of fluconazole","volume":"24","author":"Debruyne","year":"1993","journal-title":"Clin Pharmacokinet."},{"key":"B120","doi-asserted-by":"publisher","first-page":"5868","DOI":"10.1128\/AAC.00424-11","article-title":"Populationpharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets","volume":"55","author":"Patel","year":"2011","journal-title":"Antimicrob Agents Chemother."},{"key":"B121","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/S2352-4642(17)30181-5","article-title":"AWARE Study Investigators, Assessment of a renal angina index forprediction of severe acute kidney injury in critically ill children: a multicentre, multinational, prospective observational study","volume":"2","author":"Basu","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"key":"B122","doi-asserted-by":"publisher","first-page":"R137","DOI":"10.1186\/cc10257","article-title":"Recommended beta-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy","volume":"15","author":"Seyler","year":"2011","journal-title":"Crit Care"},{"key":"B123","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/ejhpharm-2016-001114","article-title":"Individualised antimicrobial dosing in critically ill patients undergoing continuous renal replacement therapy: Focus on total drug clearance","volume":"25","author":"Ruiz","year":"2018","journal-title":"Eur J Hosp Pharm"},{"key":"B124","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","article-title":"International Society of Anti-Infective Pharmacology and the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases. Individualised antibiotic dosing for patients who are critically ill: Challenges and potential solutions","volume":"14","author":"Roberts","year":"2014","journal-title":"Lancet Infect Dis"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.868513\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T11:21:23Z","timestamp":1650972083000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.868513\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,26]]},"references-count":124,"alternative-id":["10.3389\/fped.2022.868513"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.868513","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,26]]},"article-number":"868513"}}